Your session is about to expire
← Back to Search
Nucleoside Analog
MT1621 for Thymidine Kinase Deficiency
Phase 3
Waitlist Available
Research Sponsored by Zogenix MDS, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Study Summary
This study is evaluating whether a drug called MT1621 can improve the health of children with a rare genetic disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of subjects acquiring a Motor Milestone
Secondary outcome measures
Survival
Time to Acquisition of a Motor Milestone
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Male and female Participants <18 years
Find a Location
Who is running the clinical trial?
Zogenix MDS, Inc.Lead Sponsor
3 Previous Clinical Trials
146 Total Patients Enrolled
Modis Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
146 Total Patients Enrolled
Zogenix, Inc.Industry Sponsor
24 Previous Clinical Trials
2,573 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger